Subject: Merrill Lynch & Co., Inc. Convertible Securities

Information on the Notes


As more fully set forth in the Issuer’s Prospectus and Prospectus Supplement (SEC Registration #333-122639), each $1000 principal amount of the securities will be deemed a “Unit” for purposes of trading and transfer. The notes are designed for investors who want to participate in possible increases in the value of the Pharmaceutical HOLDRs. The notes are 100% principal protected. The notes are callable at the option of Merrill Lynch & Co., on or after September 7, 2007. There will be no payments prior to the maturity date unless the Notes are called or exchanged. The Notes will be payable in cash or Pharmaceutical HOLDRs.

On the maturity date or when elected to call the Notes, for each $1,000 principal amount per unit of the holders Notes, the holders will be paid an amount in cash equal to the greater of:

- The product of the exchange ratio and the average closing price of one unit of Pharmaceutical HOLDRs determined shortly prior to the maturity date or call date, as applicable; or
- $1,000

The price of the Pharmaceutical HOLDRs must increase by more than a percentage expected to be between 8.00% and 12.00% after the pricing date in order for the holder to receive more than $1,000 per Note.

It is expected that the market value of the PZP.A will depend substantially on the value of the Pharmaceutical HOLDRs and be affected by a number of other interrelated factors including, among other things: the general level of interest rates, the volatility of the Index, the time remaining to maturity, the dividend yields of the stocks comprising the Index, and the credit ratings of the Issuer.
The Notes will be payable in cash or Pharmaceutical HOLDRs. The Pharmaceutical HOLDRs Trust has no obligations relating to, and does not sponsor or endorse, the notes.

Additional information, including information concerning taxation may be found in the Prospectus.

Trading in the shares on ISE is on a UTP basis and is subject to ISE equity trading rules. The shares will trade from 9:00 a.m. until 4:00 p.m. Eastern Time. Equity Electronic Access Members (“Equity EAMs”) trading the shares during the Pre-Market Session are exposed to the risk of the lack of the calculation or dissemination of underlying index value or intraday indicative value (“IIV”). For certain derivative securities products, an updated underlying index value or IIV may not be calculated or publicly disseminated in the Pre-Market hours. Since the underlying index value and IIV are not calculated or widely disseminated during Pre-Market hours, an investor who is unable to calculate implied values for certain derivative securities products during Pre-Market hours may be at a disadvantage to market professionals.

Equity EAMs also should review NASD Notice to Members 03-71 for guidance on trading these products. The Notice reminds members of their obligations to: (1) conduct adequate due diligence to understand the features of the product; (2) perform a reasonable-basis suitability analysis; (3) perform customer-specific suitability analysis in connection with any recommended transactions; (4) provide a balanced disclosure of both the risks and rewards associated with the particular product, especially when selling to retail investors; (5) implement appropriate internal controls; and (6) train registered persons regarding the features, risk and suitability of these products.

This Regulatory Information Circular is not a statutory Prospectus. Equity EAMs should consult the Trust's Registration Statement, SAI, Prospectus and the Fund’s website for relevant information.
Appendix A
Exchange-Traded Fund Symbol CUSIP Number

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Fund Name</th>
<th>CUSIP Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>PZP.A</td>
<td>Merrill Lynch &amp; Co., Inc. Convertible Securities</td>
<td>590 18Y VX6</td>
</tr>
</tbody>
</table>